Farmiblastina

Manufactured by Pfizer

Farmiblastina is a specialized laboratory equipment designed for use in cell culture and biotechnology applications. It serves as an automated cell culture system, facilitating the cultivation and expansion of various cell lines. The core function of Farmiblastina is to provide a controlled and standardized environment for cell growth and maintenance.

Automatically generated - may contain errors

Lab products found in correlation

Taxotere, by Sanofi (2 mentions) Kadcyla, by Roche (1 mentions) Infinite m200 pro multimode microplate reader, by Tecan (1 mentions)

5 protocols using farmiblastina

Generating Genetically Diverse Mouse Cohorts for Breast Cancer Research

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

A genetically heterogeneous mouse cohort was generated by backcrossing two inbred strains as previously described.
³⁵ (link) Briefly, we crossed the breast cancer‐resistant C57BL/6 mouse strain (C57) with an FVB/N‐Tg(MMTVneu)202Mul/J susceptible strain (FVB). F1‐Neu⁺ males generated with the transgene were mated with FVB non‐transgenic females to obtain a backcrossed cohort of MMTV‐ErbB2 mice (BX‐Neu⁺) (N = 147). The concentration of tail DNA was measured using a Nanodrop ND‐1000 Spectrophotometer and used for genotyping.
³⁵ (link)
Tumour cells from BX‐Neu⁺ mice were transplanted into F1 female recipients and 100 μL of a single‐cell suspension containing 2−5 × 10⁶ cells was injected into both inguinal flanks of each mouse. Each tumour was transplanted into two individuals (N = 125). Chemotherapy was initiated when the tumour diameter reached 12 mm by treating 58 mice with docetaxel (25 mg/kg; Taxotere, Sanofi Aventis) and 69 mice with doxorubicin (5 mg/kg; Farmiblastina, Pfizer), and each drug was injected intraperitoneally (IP). Docetaxel and doxorubicin were administered every 8 and 10 days, respectively, and the mice were sacrificed when the tumour reached 25 mm in diameter or 2 months after the end of the treatment.

Mendiburu‐Eliçabe M., García‐Sancha N., Corchado‐Cobos R., Martínez‐López A., Chang H., Hua Mao J., Blanco‐Gómez A., García‐Casas A., Castellanos‐Martín A., Salvador N., Jiménez‐Navas A., Pérez‐Baena M.J., Sánchez‐Martín M.A., Abad‐Hernández M.D., Carmen S.D., Claros‐Ampuero J., Cruz‐Hernández J.J., Rodríguez‐Sánchez C.A., García‐Cenador M.B., García‐Criado F.J., Vicente R.S., Castillo‐Lluva S, & Pérez‐Losada J. (2024). NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence. Clinical and Translational Medicine, 14(2), e1554.

+ Open protocol

+ Expand

Doxorubicin Administration Protocol for Cardiac Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols

Doxorubicin was administered according to a previously detailed protocol.¹⁶ (link) In brief, animals were anaesthetized (20 mg/kg of ketamine, 2 mg/kg of xylazine, and 0.5 mg/kg of midazolam by intramuscularily injection) and maintained with intravenously perfusion of the same anaesthetics cocktail (per hour) they were also endotracheally intubated. Intramuscular buprenorphine (0.01 mg/kg) was also intramuscular administrated before the catheterism. The right femoral artery was then repeatedly accessed in each catheterization by the Seldinger technique, and a 5-Fr sheath was inserted. Pigs were anticoagulated with 150 IU/kg of intravenous heparin, and a 4-Fr coronary diagnostic catheter was inserted via a femoral sheath and placed at the origin of the left coronary artery. Under angiography guidance, a 0.014 mm coronary guide wire was positioned distally in the left anterior descending (LAD) coronary artery. The catheter was docked selectively in the proximal LAD, and a 0.45 mg/kg dose of doxorubicin (Farmiblastina^®, Pfizer) diluted in 30 mL saline was given as a slow bolus injection over 3 min. Electrocardiographic and haemodynamic parameters were monitored during doxorubicin administration. Once infusion was complete, normal coronary flow was documented by coronary angiography, the material was removed, and the animal was allowed to recover.

Galán-Arriola C., Villena-Gutiérrez R., Higuero-Verdejo M.I., Díaz-Rengifo I.A., Pizarro G., López G.J., de Molina-Iracheta A., Pérez-Martínez C., García R.D., González-Calle D., Lobo M., Sánchez P.L., Oliver E., Córdoba R., Fuster V., Sánchez-González J, & Ibanez B. (2020). Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity. Cardiovascular Research, 117(4), 1132-1143.

+ Open protocol

+ Expand

Doxorubicin Administration and Monitoring in Animal Model

Check if the same lab product or an alternative is used in the 5 most similar protocols

Doxorubicin was administered as reported previously.¹¹ (link) Briefly, animals were anaesthetized (20 mg/kg of ketamine, 2 mg/kg of xylazine, and 0.5 mg/kg of midazolam by intramuscular injection) and maintained with intravenously perfusion of the same anaesthetics cocktail (per hour) they were also endotracheally intubated. Intramuscular buprenorphine (0.01 mg/kg) was also intramuscular administrated before the catheterism. The femoral artery was then accessed by the Seldinger technique, a 7-Fr sheath was inserted, and 150 UI/kg of intravenous heparin was administrated. A 5-Fr coronary catheter was inserted through the femoral sheath and placed at the origin of the left coronary artery. Under angiography guidance, a 0.014 mm coronary guidewire was positioned distally in the left anterior descending (LAD) coronary artery, and the catheter was docked in the proximal LAD. A 0.45 mg/kg dose of doxorubicin (Farmiblastina^®, Pfizer) diluted in 30 mL saline was given as a slow bolus injection over 3 min, and a coronary angiography was recorded after infusion. Monitoring of electrocardiography and systemic blood pressure revealed no changes during doxorubicin infusion.
In animals receiving serial doxorubicin doses 2 weeks apart, the procedure was alternated between the right and left arterial femoral routes to reduce vascular complications.

Galán-Arriola C., Vílchez-Tschischke J.P., Lobo M., López G.J., de Molina-Iracheta A., Pérez-Martínez C., Villena-Gutiérrez R., Macías Á., Díaz-Rengifo I.A., Oliver E., Fuster V., Sánchez-González J, & Ibanez B. (2021). Coronary microcirculation damage in anthracycline cardiotoxicity. Cardiovascular Research, 118(2), 531-541.

+ Open protocol

+ Expand

Genetically Heterogeneous Mouse Model for Breast Cancer

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

A genetically heterogeneous mouse cohort was generated by backcrossing two inbred strains as previously described (35 (link)). Briefly, we crossed the breast cancer-resistant C57BL/6 mouse strain (C57) with an FVB/N-Tg(MMTVneu)202Mul/J susceptible strain (FVB). F1-Neu⁺ males generated with the transgene were mated with FVB non-transgenic females to obtain a backcrossed cohort of MMTV-ErbB2 mice (BX-Neu⁺) (N = 147). The concentration of tail DNA was measured using a Nanodrop ND-1000 Spectrophotometer and used for genotyping. (35 (link))
Tumor cells from BX-Neu⁺ mice were transplanted into F1 female recipients and 100 μL of a single-cell suspension containing 2–5 ×10⁶ cells was injected into both inguinal flanks of each mouse. Each tumor was transplanted into two individuals (N = 125). Chemotherapy was initiated when the tumor diameter reached 12 mm by treating 58 mice with docetaxel (25 mg/kg; Taxotere, Sanofi Aventis) and 69 mice with doxorubicin (5 mg/kg; Farmiblastina, Pfizer), and each drug was injected intraperitoneally (IP). Docetaxel and doxorubicin were administered every 8 and 10 days, respectively, and the mice were sacrificed when the tumor reached 25 mm in diameter or two months after the end of the treatment.

Mendiburu-Eliçabe M., García-Sancha N., Corchado-Cobos R., Martínez-López A., Chang H., Mao J.H., Blanco-Gómez A., García-Casas A., Castellanos-Martín A., Salvador N., Jiménez-Navas A., Pérez-Baena M.J., Sánchez-Martín M.A., Abad-Hernández M.D., Del Carmen S., Claros-Ampuero J., Cruz-Hernández J.J., Rodríguez-Sánchez C.A., García-Cenador M.B., García-Criado F.J., Vicente R.S., Castillo-Lluva S, & Pérez-Losada J. (2023). NCAPH Drives Breast Cancer Progression and Identifies a Gene Signature that Predicts Luminal A Tumor Recurrence. Research Square.

+ Open protocol

+ Expand

Cytotoxicity Assay of Anticancer Agents

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tumor cells were seeded as described above. After 24 h cells were treated with different concentrations of paclitaxel (#33069-62-4, Paclitaxel Hospira, Pfizer), doxorubicin (#23214-92-8, Farmiblastina, Pfizer), or T-DM1 (#1018448-65-1, Kadcyla, Roche). Treatment lasted for 3 days in the case of the chemotherapeutic agents paclitaxel and doxorubicin, and 6 days when treated with T-DM1. Cell death was assayed by crystal violet staining of alive cells and read at the Infinite M200 Pro Multimode Microplate Reader (TECAN).

Arenas E.J., Martínez-Sabadell A., Rius Ruiz I., Román Alonso M., Escorihuela M., Luque A., Fajardo C.A., Gros A., Klein C, & Arribas J. (2021). Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. Nature Communications, 12, 1237.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!